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C (2) were isolated along with previously reported cyslabdan (cyslabdan A (3) in this study) from
the culture broth of Streptomyces sp. K04-0144. The structure was elucidated by various
spectroscopy including NMR, revealing that 1 and 2 was 18-hydroxy and 10-methoxy cyslabdan,
respectively. Compounds 1 and 2 were found to potentiate imipenem activity against methicillin-
resistant Staphylococcus aureus by 123 fold and 533 fold, respectively. Comparison with the activity
of compound 3 indicated that the introduction of a hydrophilic group at the dimethyl moiety of the
decalin ring was unfavorable for its activity.
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Methicillin-resistant Staphylococcus aureus (MRSA), a major
and widespread pathogen in hospitals, has developed resis-
tance to many other antibiotics1. Moreover, MRSA getting
resistant to the last-resort antibiotic, vancomycin, has been
reported2,3. These facts suggest that MRSA would acquire
more resistance to vancomycin in the near future. It is
therefore increasingly important and necessary to ﬁnd new
antimicrobial agents and to devise new measures that are
effective against MRSA infection.
Based on the new concept of ‘‘anti-infective drugs’’ devel-
oped by Omura4, a screening system was established to search
for microbial potentiators of imipenem activity against
MRSA5, and new cyslabdan (cyslabdan A (3) in this study)
was previously discovered from the culture broth ofFigure 1 Structures of compounds.
Table 1 Physico-chemical properties of 1 and 2.
Items Compound 1
Apperance White powder
Molecular weight 483
Molecular formula C25H41NO6S
HR-FAB-MS (m/z)
Found 484.2730 [MþH]þ
Calcd. 484.2728
½a27D þ22.2 (c 0.1, CH3OH)
UVlCH3OHmax nmðlogeÞ 233 (4.30)
IRnKBrmax cm
1 3427, 2940, 2883, 1741, 1633, 139
Solubility
Soluble H2O, CH3CN, CH3OH, EtOAc
Insoluble CHCl3, n-HexaneStreptomyces sp. K04-01446,7. From further precise analysis
of the culture broth, new congeners cyslabdans B (1) and C (2)
were recently discovered (Fig. 1). In this study, the isolation,
structural elucidation, and biological properties of 1 and 2 are
described.2. Results and discussion
2.1. Structural elucidation of 1 and 2
The physico-chemical properties of 1 and 2 are summarized in
Table 1. Compounds 1 and 2 showed UV absorption at 233 nm.
The IR absorption around 3400 cm1 and 1740 cm1 suggested
the presence of a hydroxyl residue and/or an amide residue, and a
carbonyl residue in their structures, respectively. These physico-
chemical properties are very similar to that of 3.
The structure of 1 was elucidated from various spectral data
including NMR experiments. The molecular formula of 1 was
determined as C25H41NO6S on the basis of HR-FAB-MS
measurements, indicating that 1 was bigger with one oxygen
atom than 3. The 13C NMR spectrum showed 25 resolved
peaks, which were classiﬁed into four methyl carbons, nine
methylene carbons, four sp3 methine carbons, two sp2 methine
carbons, three sp3 quaternary carbons, and three sp2 quatern-
ary carbons by DEPT spectral analysis. The 1H NMR
spectrum (in CD3OD) displayed 36 proton signals. The
connectivity of the proton and carbon atoms was established
from the HMQC spectrum (Table 2). A comparison of the
1H and 13C NMR spectra of 1 and 3 indicated that they both
possessed a labdanic skeleton. However, a methyl proton
(H3-18, d 0.91) in 3 was absent in 1, and an oxymethylene
(d 3.33, 3.76) was present in 1 which was absent in cyslabdan
A, indicating that 1 is 18-hydroxy cyslabdan A. In fact, cross
peaks were observed from H2-18 (d 3.33, 3.76) to C-3 (d 36.5),
C-4 (d 39.6), C-5 (d 54.4), and C-19 (d 27.7) in the 13C–1H
HMBC experiments (Fig. 2). The structure satisﬁed the
unsaturation number, UV spectra, and the molecular formula.
Taken together, the planar structure of 1 was elucidated as
shown in Fig. 1.
The structure of 2 was similarly elucidated. The molecular
formula of 2 is C26H43NO5S, indicating that 2 is bigger than 3
with CH2. Its
1H NMR spectrum was almost identical to thatCompound 2
White powder
481
C26H43NO5S
482.2934 [MþH]þ
482.2927
þ11.8 (c 0.1, CH3OH)
233 (4.12)
6, 1132 3419, 2931, 2873, 1738, 1657, 1381, 1135
H2O, CH3CN, CH3OH, EtOAc
CHCl3, n-Hexane
Figure 2 Key HMBC of compound 1.
Table 2 1H and 13C NMR chemical shifts of 1 and 2 in CD3OD (
1H NMR, 400 MHz).
Compound 1 Compound 2
Position dC dH Position dC dH
1 41.1 0.92 (1H, m) 1 41.1 0.87 (1H, m)
1.71 (1H, m) 1.67 (1H, m)
2 19.0 1.39 (1H, m) 2 19.3 1.39 (1H, m)
1.59 (1H, m) 1.62 (1H, m)
3 36.5 0.93 (1H, m) 3 43.0 1.18 (1H, m)
1.84 (1H, m) 1.42 (1H, m)
4 39.6 4 34.1
5 54.4 1.02 (1H, m) 5 53.9 0.87 (1H, m)
6 27.8 1.62 (1H, m) 6 28.0 1.59 (1H, m)
1.81 (1H, m) 1.70 (1H, m)
7 73.1 3.67 (1H, dd, J¼4.5, 11.0) 7 73.0 3.69 (1H, dd, J¼4.5, 11.0)
8 78.6 8 78.6
9 55.2 1.34 (1H, m) 9 55.1 1.31 (1H, m)
10 39.8 10 39.9
11 24.6 2.08 (1H, m) 11 24.3 2.07 (1H, m)
2.44 (1H, dt, J¼6.5, 17.0) 2.45 (1H, dt, J¼6.5, 17.0)
12 137.4 5.50 (1H, t, J¼6.5) 12 137.5 5.49 (1H, t, J¼6.5)
13 133.5 13 133.5
14 143.0 6.35 (1H, dd, J¼10.0, 18.0) 14 143.1 6.35 (1H, dd, J¼10.0, 18.0)
15 110.4 4.86 (1H, d, J¼10.0) 15 110.3 4.86 (1H, d, J¼10.0)
5.05 (1H, d, J¼18.0) 5.04 (1H, d, J¼18.0)
16 12.1 1.76 (3H, br-s) 16 12.1 1.76 (3H, br-s)
17 39.0 2.59 (1H, d, J¼12.5) 17 39.0 2.57 (1H, d, J¼12.5)
2.77 (1H, d, J¼12.5) 2.76 (1H, d, J¼12.5)
18 65.0 3.33 (1H, d, J¼10.0) 18 34.0 0.92 (3H, s)
3.76 (1H, d, J¼10.0)
19 27.7 0.98 (3H, s) 19 22.3 0.86 (3H, s)
20 16.7 0.96 (3H, s) 20 15.9 1.00 (3H, s)
10 173.9 10 172.7
20 53.8 4.54 (1H, dd, J¼4.5, 8.0) 20 53.9 4.55 (1H, dd, J¼4.5, 8.0)
30 36.4 2.80 (1H, dd, J¼8.0, 13.0) 30 36.2 2.77 (1H, dd, J¼8.0, 13.0)
3.02 (1H, dd, J¼4.5, 13.0) 2.97 (1H, dd, J¼4.5, 13.0)
40 173.2 40 173.2
50 22.4 1.98 (3H, s) 50 22.3 1.98 (3H, s)
60 52.9 3.72 (3H, s)
Figure 3 Key HMBC of compound 2.
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(d 3.72) in 2, indicating that one of the hydroxyl groups of 3
was methylated in 2. The position of the methylation was
conﬁrmed by 13C–1H HMBC experiments (Fig. 3): cross peaks
were observed from H3-6
0 (d 3.72), H-20 (d 4.55), and H-30
(d 2.77, 2.97) to C-10 (d 172.7). Thus, compound 2 was
elucidated to be 10-methoxy cyslabdan A (Fig. 1).Regarding the stereochemistry of 1 and 2, the data from the
ROESY experiments were consistent with those of 36. The
relative conﬁguration of the labdane skeleton in 1 and 2 was
shown to be identical to that of 3; i.e., (12E)-labda-12, 14-dien-
7b,8adiol (Fig. 1). The stereochemistry of N-acetylcysteine
was also deﬁned as L6. This is reasonable because they share
the same biosynthetic pathway.
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The potentiation of imipenem activity against MRSA was
investigated by the liquid microdilution method5,8. The con-
centrations of 1 and 2 were set to 10 mg/mL, which had no
effect on the growth of MRSA. Compounds 1 and 2 both
demonstrated potentiating activity, reducing the MIC value of
imipenem from 16 to 0.13 (123-fold potentiation) and 0.03 mg/mL
(533-fold potentiation), respectively. Taking the activity of 3
(1070-fold potentiation) into consideration, the introduction of a
hydrophilic group at the dimethyl moiety of the decalin ring might
have an unfavorable effect on its activity. Further studies of the
structure-activity relationship of cyslabdans and their mechanisms
of action of 3 are ongoing.3. Experimental
3.1. Materials
The following materials were purchased from commercial
sources: Mueller-Hinton broth (MHB, Difco) and imipenem
(Banyu Pharmaceutical).
3.2. General procedures
Streptomyces sp. K04-0144 was used for production of 1 and
26,7. UV spectra were recorded on a spectrophotometer (8453
model, Agilent). IR spectra were recorded on a Fourier trans-
form infrared spectrometer (FT-710, Horiba). Optical rotations
were measured with a digital polarimeter (DIP-370, JASCO).
FAB-MS spectra and HR-FAB-MS spectra were recorded on a
mass spectrometer (JMS-AX505HA, JEOL). The various NMR
spectra were collected with a spectrometer (XL-400, Varian).
3.3. Isolation of compounds 1 and 2
Five-day old fermentation broth (110 L) of Streptomyces sp.
K04-0144 was centrifuged to separate the mycelia and super-
natant. The supernatant was then applied to a 2.5 L Diaion
HP-20 column (Mitsubishi Chemical Co.). After washing
with water, the desired substances were eluted with MeOH
and concentrated in vacuo to dryness to produce brown oily
materials (15.8 g), which were then dissolved in MeOH and
applied to an ODS column (40 g, Senshu Scientiﬁc Co.). The
substances were eluted stepwise with 20%, 40%, 60%, 80%,
and 100% MeOH (each 1.5 L). The 80% MeOH fraction
containing 1–3 was concentrated in vacuo to dryness to yield
brown substances (1.7 g), which were then puriﬁed using
HPLC (column: PEGASIL ODS, 20 mm 250 mm (Senshu
Scientiﬁc Co.); solvent: 55% CH3CN containing 0.05% TFA;
detection: UV at 230 nm; ﬂow: 6.0 mL/min). Under these
conditions, the fractions of the peaks eluted at retention times
of 10.0 and 58.8 min were repeatedly collected and were
concentrated to dryness to give brown oils A (930 mg) and
B (46.5 mg), respectively. Brown oil A was rechromato-
graphed using HPLC (under the same conditions as described
above except that the solvent was 35% CH3CN containing
0.05% TFA). The peak with a retention time of 43.0 min was
collected and concentrated to give pure 1 as a white powder
(18.7 mg). Brown oil B was also rechromatographed using HPLC(column: C30-UG5, 20 mm 250 mm (Nomura Scientiﬁc);
solvent: 70% CH3CN containing 0.05% TFA; detection: UV at
210 nm; ﬂow: 6.0 mL/min), and the fractions of the peaks eluted
at 30.5 and 49.6 min were collected to give pure 2 (2.5 mg) and 3
(31.2 mg) as white powders.
3.4. Assay for potentiating activity of imipenem
against MRSA
Potentiating activity of imipenem against MRSA in combination
with cyslabdans was investigated by the liquid microdilution
method as our previously reported5,8. Brieﬂy, MHB (85 mL) was
added to each well of a 96-well microtiter plate (Corning), sample
dissolved in MeOH (5.0 mL) was added to the ﬁnal concentration
of 10 mg/mL, whose concentration has no effect on growth of
MRSA. Then, imipenem (5.0 mL) serially diluted dissolved in
with distilled water (5.0 mL) were added to each well to make the
ﬁnal concentrations of 0.0005 to 512 mg/mL. After MRSA
(5.0 mL) was added at the concentration of 1.0 107 CFU/mL,
microtiter plates were incubated at 37 1C for 20 h. MIC values
were determined in the presence or absence of sample.
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